Biotech Stock Rips On FDA Fast Track

Biotech Stock Rips On FDA Fast Track

By: Dylan Sikes – News

Monday, February 22, 2021

A New Jersey-based biotech stock absolutely ripped today after it announced that the company received Fast Track designation from the U.S. Food and Drug Administration (FDA) for GEN-1, its DNA-mediated interleukin-12 immunotherapy. Celsion Corporation’s (Nasdaq:CLSN) GEN-1 is currently in Phase II development for the treatment of advanced ovarian cancer. 

Celsion Corp is active in the biotechnology market. The company acts as a drug developer with product candidates like ThermoDox, a heat-activated liposomal encapsulation of doxorubicin. It is in Phase III clinical trial for the treatment of primary liver cancer and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer. Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers.

Traders were extremely enthusiastic on the positive news as shares traded up to a session high of $3.25/share (+71%) following the headline. This move snapped a recent pullback and propelled the stock back into its uptrend that it has been riding for months.

Copyright © 2021 All rights reserved. Republication or redistribution of's content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Aerospace Shares Pop On Strategic Partnership
Healthcare Shares Pop On New Contract
Florida-Based Company To Supply Brazilian Federal Police With Detection Technology
Most Popular
FREE Newsletter

Back to Top